

Transparency Reporting at Kyowa Kirin AB Methodological Note for 2025 data

1. Introduction

Kyowa Kirin AB is committed to supporting healthcare and the development of patient care in Lithuania.

We do this through the provision of financial and non-financial support to Healthcare Organizations (HCOs), Patient Organizations (POs), or Healthcare Professionals (HCPs). We also engage and pay HCOs, POs and HCPs for services that contribute to the improvement of patient care.

Provision of support and payments for services are referred to as 'Transfers of Value' (ToVs). In accordance with Article 51¹ of Pharmaceutical Law of the Republic of Lithuania and Code of Ethics for Pharmaceutical Marketing, adopted by the Association of the Manufacturers of Medicinal Products and by the Innovative Pharmaceutical Industry Association (Lithuanian Code of Ethics), Kyowa Kirin AB annually discloses details of ToVs to these individuals and organizations.

When declaring ToVs, Kyowa Kirin AB follows Article 51¹ of the Pharmaceutical Law of the Republic of Lithuania and the Description of the procedure for providing information on transferred values to recipients, legal entity data, and personal data of healthcare and/or pharmaceutical specialists to the State Medicines Control Agency, as well as the procedure for publishing information on transferred values and personal data of healthcare and/or pharmaceutical specialists, approved by the order of the Minister of Health of the Republic of Lithuania on June 23, 2020, No. V-1537. Kyowa Kirin AB provides the State Medicines Control Agency with information about the values transferred to healthcare and/or pharmaceutical specialists, legal entities (transferred value recipients), and the State Tax Inspectorate with information about the support related to healthcare provided during the previous year. All this information is published on the State Medicines Control Agency's website: [Perleistas vertės - Valstybinė vaistų kontrolės tarnyba prie LR Sveikatos Apsaugos Ministerijos](#)

Disclosures about aggregated transfer of values for Research and development, as well as transfer of values to POs are only required to be made under the Lithuanian Code of Ethics.

2. Definition

2.1 Recipients

Healthcare Organizations (HCOs): Any healthcare, medical or scientific association or organization such as a hospital, foundation, university or other teaching institution or learned society (except for those who qualify as a Patient Organizations) through which one or more HCPs provide services.

Patient Organizations (POs): Not for profit organization (including the umbrella organizations to which they belong) mainly composed of patients and /or caregivers that represent and /or support the needs of patients and /or caregivers.

Healthcare Professionals (HCPs): Any individual or entity that is a member of medical, dental, pharmacy or nursing professions or any other person who, in the course of his or her professional activities, may prescribe, purchase, supply, recommend or administer a medicinal product.

For the avoidance of doubt, the definition of HCP includes: (i) any official or employee of a government agency or other organization (whether in the public or private sector) that may

prescribe, purchase, supply or administer medicinal products and (ii) any employee of a Member Company whose primary occupation is that of a practicing HCP, but excludes (a) all other employees of a Member Company and (b) a wholesaler or distributor of medicinal products.

2.2 Kind of ToVs

This disclosure includes the following ToVs:

EFPIA* Category	Examples
Fees for contracted services and related expenses for POs	• Chairing and/or attending Advisory Boards or expert meetings • Speaking engagements • Consultancy arrangements related to patient recruitment
	Travel and accommodation expenses relating to the activities above
Financial support to POs	• Sponsorships of events organized by a PO • Funding to attend conferences and events
Non-financial support to POs	In-kind donations
Research and Development	Activities relating to i) the planning or conduct of non-clinical studies; ii) clinical trials, iii) non-interventional studies that are prospective in nature; iv) clinical investigators' meetings

* European Federation of Pharmaceutical Industries & Associations

If activities relate to retrospective non-interventional studies, related ToVs are included in Fees for Service, rather than Research and Development.

3. Disclosure's Scope

3.1 Products concerned

Medicinal products

3.2 Company concerned

Each Kyowa Kirin affiliate, in countries where the EFPIA code is applicable, is accountable for capturing and validating ToV data in their nation, and one disclosure is made per nation.

3.3 ToVs Date

This disclosure covers ToVs between 1st January 2025 to 31st December 2025 to POs which are registered in Lithuania and R&D related TOVs.

3.4 Cross-border activities

Kyowa Kirin makes best efforts to capture and report all ToVs to HCPs, POs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's country of principal practice or the HCO's or PO's country of registration.

3.5 R&D

Fees and expenses (e.g., travel and accommodation) are provided to a healthcare professional (HCP) or healthcare organization (HCO) for the provision of services related to R&D related activities (pre-clinical studies, clinical trials or non-interventional studies).

3.6 Voluntary disclosure

N/A

4. Specific considerations

4.1 Country unique identifier

N/A

4.2 Multi-year agreements

For multi-year agreements, disclosures are made based on the date each payment is executed, regardless of the overall contract duration.

4.3 Country specificities

N/A

4.4 Quality Checks (optional for pre-disclosure)

Kyowa Kirin AB conducts a quality review of completed Disclosable ToVs during the Report Generation process, including completeness and accuracy checks.

5. Data protection legal basis

5.1 Consent collection

In Lithuania, ToVs to HCOs and POs are reported without the need for consent from these HCOs, as they are legal entities.

5.2 Legitimate interest

HCPs' ToVs are processed based on legal obligation.

6. Form of disclosure

6.1 Date of publication

- (1) Reports on transfer of values to HCPs and HCOs shall be provided by Kyowa Kirin to the State Medicine Control Agency (reports are due by 30 June), except information on values transferred as donation or charity under the Law on Charity and Sponsorship of the Republic of Lithuania. Values transferred as Sponsorship to HCOs shall be provided to the State Medicine Control Agency by the State Tax Inspectorate, based on reports of the recipients of transferred values. This information on values transferred to HCPs and HCOs shall be published on the website of the State Medicines Control Agency (including personal data of HCPs and names of entities / HCOs).
- (2) The reports on transfer of values to POs and aggregated transfer of values for Research and development shall be disclosed by publishing the reports on transfers of value by Kyowa Kirin (the reports must be published between 20 and 30 June each

year).

6.2 Disclosure platform

TOVs to HCPs and HCOs are published on SMCA website:

[Perleistas vertės - Valstybinė vaistų kontrolės tarnyba prie LR Sveikatos Apsaugos Ministerijos](#)

Information of transfers of value for POs and R&D are published on on Kyowa Kirin's homepage.

6.3 Disclosure language

Disclosure on SMCA website is in Lithuanian language. The disclosure reports published on Kyowa Kirin's website are in Lithuanian. The Methodological Note is available in Lithuanian and English.

7. Disclosure financial data

7.1 Currency (local or if not, specify the exchange rate)

The currency used for disclosure is euro. In the case that payments are made in a currency other than euro the payment amount is converted to euro using the daily exchange rate between the two currencies on the day of payment.

7.2 VAT included or exclude

All ToVs include VAT where applicable.

7.3 Calculation rules (e.g., in-kind ToVs)

The date of the ToVs included in this disclosure is the date of payment (where the ToV is payment); if the ToV is a benefit in kind, it is based on the date the recipient received the benefit.

8. Additional information

Any questions regarding this disclosure should be directed to infose@kyowakirin.com.